Brief: Irlab Therapeutics: New Preclinical Data Indicate Phase IIb Drug Candidate Mesdopetam's Efficacy In Parkinson's Psychosis And Pd-Lids

IRLAB Therapeutics AB

15/11/2022 16:05

Nov 15 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB THERAPEUTICS - NEW PRECLINICAL DATA INDICATING PHASE IIB DRUG CANDIDATE MESDOPETAM'S
EFFICACY IN PARKINSON'S PSYCHOSIS AND PD-LIDS

Source text for Eikon:  ID:nMFN63zvcq 
Further company coverage:  IRLABa.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))